ANN ARBOR, MI--(Marketwire - November 05, 2007) - Pipex Pharmaceuticals, Inc. (AMEX: PP) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced the presentation of preliminary results using its lead anti-copper drug candidate, COPREXA (oral tetrathiomolybdate), in the most commonly utilized transgenic pre-clinical murine model of Alzheimer’s Disease (AD) at the 2007 Society for Neuroscience annual meeting on November 4th in San Diego, CA. These studies were funded by a grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
